Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Daiichi Sankyo2022-12-09 10:53:06Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR
-
Daiichi Sankyo2022-12-08 13:03:04ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus
-
Daiichi Sankyo2022-09-06 16:18:42Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMO
-
Daiichi Sankyo2022-08-18 15:27:02ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice
-
Daiichi Sankyo2022-08-18 15:16:38ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More
-
Daiichi Sankyo2022-08-18 15:09:25Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic
-
Daiichi Sankyo2022-06-23 16:27:20Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic
-
Daiichi Sankyo2022-06-07 17:50:00DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma
-
Daiichi Sankyo2022-06-07 17:41:49ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low
-
Daiichi Sankyo2022-06-03 15:23:19Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic